SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc. is in a strong position in acute myeloid leukemia (AML) with positive data from a Phase IIa study of SLS009 and the completion of enrollment in its Phase III trial of

Clinical Trial Integrity When I worked in one of the world’s biggest CROs, its strict data security and trial integrity policies were all part of the on-boarding process even for those of us working i

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Jazz Moves Into IO With Engineered IFN⍺

Since 2017, nine new drugs have been approved for acute myeloid leukemia (AML) in the US, dramatically changing the treatment landscape, with the condition benefiting from breakthroughs in the underst